Incorporation of Host Complement Regulatory Proteins into Newcastle Disease Virus Enhances Complement Evasion

被引:39
作者
Biswas, Moanaro [1 ]
Johnson, John B. [2 ]
Kumar, Sandeep R. P. [1 ]
Parks, Griffith D. [2 ]
Subbiah, Elankumaran [1 ]
机构
[1] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA
[2] Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27103 USA
关键词
ONCOLYTIC VIRUS; ENVELOPED VIRUSES; VACCINIA VIRUS; ACTIVATION; CD55; INACTIVATION; CANCER; CELLS; CD46; C3B;
D O I
10.1128/JVI.00886-12
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学];
摘要
Newcastle disease virus (NDV), an avian paramyxovirus, is inherently tumor selective and is currently being considered as a clinical oncolytic virus and vaccine vector. In this study, we analyzed the effect of complement on the neutralization of NDV purified from embryonated chicken eggs, a common source for virus production. Fresh normal human serum (NHS) neutralized NDV by multiple pathways of complement activation, independent of neutralizing antibodies. Neutralization was associated with C3 deposition and the activation of C2, C3, C4, and C5 components. Interestingly, NDV grown in mammalian cell lines was resistant to complement neutralization by NHS. To confirm whether the incorporation of regulators of complement activity (RCA) into the viral envelope afforded complement resistance, we grew NDV in CHO cells stably transfected with CD46 or HeLa cells, which strongly express CD46 and CD55. NDV grown in RCA-expressing cells was resistant to complement by incorporating CD46 and CD55 on virions. Mammalian CD46 and CD55 molecules on virions exhibited homologous restriction, since chicken sera devoid of neutralizing antibodies to NDV were able to effectively neutralize these virions. The incorporation of chicken RCA into NDV produced in embryonated eggs similarly provided species specificity toward chicken sera.
引用
收藏
页码:12708 / 12716
页数:9
相关论文
共 50 条
[1]
Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells [J].
Barilla-LaBarca, ML ;
Liszewski, MK ;
Lambris, JD ;
Hourcade, D ;
Atkinson, JP .
JOURNAL OF IMMUNOLOGY, 2002, 168 (12) :6298-6304
[2]
The relevance of complement to virus biology [J].
Blue, CE ;
Spiller, OB ;
Blackbourn, DJ .
VIROLOGY, 2004, 319 (02) :176-184
[3]
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: No shortcuts on the road to approval [J].
Breitbach, Caroline J. ;
Reid, Tony ;
Burke, James ;
Bell, John C. ;
Kirn, David H. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2010, 21 (2-3) :85-89
[4]
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H [J].
Chung, Kyung Min ;
Liszewski, M. Kathryn ;
Nybakken, Grant ;
Davis, Alan E. ;
Townsend, R. Reid ;
Fremont, Daved H. ;
Atkinson, John P. ;
Diamond, Michael S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (50) :19111-19116
[5]
Coukos G, 1999, CLIN CANCER RES, V5, P1523
[6]
FUNCTION OF CLASSICAL AND ALTERNATE PATHWAYS OF HUMAN COMPLEMENT IN SERUM TREATED WITH ETHYLENE-GLYCOL TETRAACETIC ACID AND MGCL2-ETHYLENE GLYCOL TETRAACETIC ACID [J].
DESPREZ, RM ;
BRYAN, CS ;
HAWIGER, J ;
COLLEY, DG .
INFECTION AND IMMUNITY, 1975, 11 (06) :1235-1243
[7]
Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death [J].
Elankumaran, Subbiah ;
Rockemann, Daniel ;
Samal, Siba K. .
JOURNAL OF VIROLOGY, 2006, 80 (15) :7522-7534
[8]
Recent deal highlights hopes for cancer-killing viruses [J].
Evans, Jon .
NATURE MEDICINE, 2011, 17 (03) :268-269
[9]
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme [J].
Freeman, AI ;
Zakay-Rones, Z ;
Gomori, JM ;
Linetsky, E ;
Rasooly, L ;
Greenbaum, E ;
Rozenman-Yair, S ;
Panet, A ;
Libson, E ;
Irving, CS ;
Galun, E ;
Siegal, T .
MOLECULAR THERAPY, 2006, 13 (01) :221-228
[10]
Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1 [J].
Friedman, HM ;
Wang, LY ;
Pangburn, MK ;
Lambris, JD ;
Lubinski, J .
JOURNAL OF IMMUNOLOGY, 2000, 165 (08) :4528-4536